17542-47-1

Basic information

• Product Name: N-benzyl-2-chloro-N-methylethanamine
• Synonyms: Benzylamine, N-(2-chloroethyl)-N-methyl-
• CAS NO: 17542-47-1
• Molecular Formula: C₁₀H₁₄ClN
• Molecular Weight: 183.6779
• Mol File: 17542-47-1.mol

Chemical Properties

• Boiling Point: 205.3°C at 760 mmHg
• Flash Point: 77.9°C
• Density: 1.056g/cm³
• Vapor Pressure: 0.252mmHg at 25°C
• Refractive Index: 1.529
• CAS DataBase Reference: N-benzyl-2-chloro-N-methylethanamine(CAS DataBase Reference)
• NIST Chemistry Reference: N-benzyl-2-chloro-N-methylethanamine(17542-47-1)
• EPA Substance Registry System: N-benzyl-2-chloro-N-methylethanamine(17542-47-1)

Safety Data

• Hazardous Substances Data: 17542-47-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-benzyl-2-chloro-N-methylethanamine is used as a key intermediate in the synthesis of various pharmaceutical drugs for its ability to facilitate the creation of complex molecular structures. It plays a critical role in the production of drugs like benzphetamine and phenmetrazine, contributing to their therapeutic effects.
Used in Agrochemical Industry:
In the agrochemical sector, N-benzyl-2-chloro-N-methylethanamine is utilized in the synthesis of pesticides, where it aids in the development of compounds that protect crops from pests and diseases, thereby ensuring agricultural productivity.
Used in Dye Production:
This chemical compound is also used as an intermediate in the production of dyes, where it contributes to the formation of colorants used in various industries, including textiles and printing.
Used in Organic Compounds Synthesis:
N-benzyl-2-chloro-N-methylethanamine is employed in the synthesis of other organic compounds, highlighting its versatility in organic chemistry and its ability to form a wide range of products used in different industries.
It is important to handle N-benzyl-2-chloro-N-methylethanamine with caution and adhere to proper safety protocols due to its toxic and corrosive nature, ensuring the safety of individuals and the environment.

Upstream product

• 107-04-0 1-Bromo-2-chloroethane 
• 103-67-3 benzyl-methyl-amine 
• 100-44-7 benzyl chloride 
• 75-77-4 chloro-trimethyl-silane 
• 37082-04-5 2-(methyl(3-phenylpropyl)amino)ethanol 
• 104-63-2 N-Benzylethanolamine 
• 101-98-4 2-(N-benzyl-N-methyl)amino-1-ethanol 
• 107-20-0 2-chloroethanal 

Downstream Products

• 56836-45-4 4-(benzyl-methyl-amino)-2-(3-methoxy-phenyl)-butyronitrile 
• 129506-74-7 4-(benzyl-methyl-amino)-2,2-diphenyl-butyronitrile 
• 101496-32-6 4-(benzyl-methyl-amino)-2-cyano-butyric acid ethyl ester 
• 855226-49-2 4-(benzyl-methyl-amino)-2-cyano-2-phenyl-butyric acid ethyl ester 
• 88207-66-3 1-<2-(N-benzyl-N-methylamino)ethyl>-1-methyl-2-tetralone ethylene acetal 
• 14165-18-5 N-benzyl-N-methylethylenediamine 
• 849472-99-7 [2-(benzylmethylamino)ethyl]carbamic acid tert-butyl ester 
• 102561-11-5 benzyl-methyl-(2-thioxanthen-9-yl-ethyl)-amine 

Relevant articles and documents

CRYSTAL FORM OF MONOMETHANESULFONATE OF DEUTERATED 3-(4,5-SUBSTITUTED AMINOPYRIMIDINE)PHENYL COMPOUND AND PREPARATION METHOD THEREFOR

Disclosed in the present invention are a crystal form of monomethanesulfonate of a deuterated 3-(4,5-substituted aminopyrimidine)phenyl compound as represented by formula I, and a preparation method therefor. The crystal form is highly stable, can be used for treatment or prevention of diseases or conditions by means of epidermal growth factor receptors (EGFRs) in some mutation forms, can effectively inhibit the growth of a variety of tumor cells, and have an inhibiting effect on other proteases of EGFR and Her families, and thus can be used for preparing antitumor drugs.

DEUTERATED 3-(4,5-SUBSTITUTED PYRIMIDINAMINE) PHENYL DERIVATIVES AND APPLICATIONS THEREOF

The present invention discloses a type of deuterated 3-(4,5-substituted aminopyrimidine)phenyl derivatives and use thereof. The derivatives are compounds of Formula (I) or pharmaceutically acceptable salts thereof. These compounds or salts thereof can be used for treatment or prevention of diseases or illnesses through certain mutant forms of epidermal growth factor receptors, inhibit the growth of various tumor cells effectively, and inhibit other proteases of EGFR and Her families, they can be used for preparing anti-tumor drugs.

C-F bond substitution via aziridinium ion intermediates

Aliphatic 1,2-aminofluorides undergo extremely fast substitution reactions under the influence of lanthanum tris(hexamethyldisilazide). The substitution proceeds via an in situ generated aziridinium ion intermediate, which subsequently undergoes ring opening by addition of a nucleophile, yielding various β-substituted amines.

NOVEL COMPOUNDS OF PROLINE AND MORPHOLINE DERIVATIVES

The present invention relates to compounds with the formulas (I), (II), and (III), or a pharmaceutically acceptable salt thereof: wherein T is a (4 to 10)-membered heterocyclyl selected from the group consisting of and wherein R1. R2 and R3 are as defined in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formulas (I), (II), and (III) and methods of treating a condition that is mediated by the modulation of the 11-β-hsd-1 enzyme, the method comprising administering to a mammal an effective amount of a compound of formulas (I), (II), and (III).

Compounds having antidiabetic, hypolipidemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them

Thiazolidinediones of formula (I) their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them having antidiabetic, hypolipidemic, and antihypertensive properties have been prepared. STR1

Design and synthesis of imidazoline derivatives active on glucose homeostasis in a rat model of type ii diabetes. 2. Syntheses and biological activities of 1,4-dialkyl-, 1,4-dibenzyl, and 1-benzyl-4-alkyl-2-(4',5'- dihydro-1'H-imidazol-2'-yl)piperazines and isosteric analogues of imidazoline

Piperazine derivatives have been identified as new antidiabetic compounds. Structure-activity relationship studies in a series of 1-benzyl- 4-alkyl-2-(4',5'-dihydro-1'H-imidazol-2'-yl)piperazines resulted in the identification of 1-methyl-4-(2',4'-dichlorobenzyl)-2-(4',5'-dihydro-1'H- imidazol-2'-yl)piperazine, PMS 812 (S-21663), as a highly potent antidiabetic agent on a rat model of diabetes, mediated by an important increase of insulin secretion independently of α2 adrenoceptor blockage. These studies were extended to find additional compounds in these series with improved properties. In such a way, substitution of both piperazine N atoms was first optimized by using various alkyl, branched or not, and benzyl groups. Second, some modifications of the imidazoline ring and its replacement by isosteric heterocycles were carried out, proceeding from PMS 812, to evaluate their influence on the antidiabetic activity. The importance of the distance between the imidazoline ring and the piperazine skeleton was studied third. Finally, the influence of the N-benzyl moiety was also analyzed compared to a direct N-phenyl substitution. The pharmacological evaluation was performed in vivo using glucose tolerance tests on a rat model of type II diabetes. The most active compounds were 1,4-diisopropyl-2-(4',5'-dihydro-1'H-imidazol-2'- yl)piperazine (41a), PMS 847 (S-22068), and 1,4-diisobutyl-2-(4',5'-dihydro- 1'H-imidazol-2'-yl)piperazine (41b), PMS 889 (S-22575), which strongly improved glucose tolerance without any side event or hypoglycemic effect. More particularly, PMS 847 proved to be as potent after po (100 μmol/kg) as after ip administration and appears as a good candidate for clinical investigations.

Thiazolidinedione derivatives having antidiabetic, hypolipidaemic antihypertensive properties, process for their preparation and pharmaceutical compositions containing them

A compound of the general formula (I), where A represents, substituted or unsunstituted unsaturated aliphatic, alicyclic, aromatic, heterocyclic groups, B represents a substituted or unsubstituted divalent alkylene or alkenyl group having 1 to 10 carbon atoms, wherein substituents may be present in one or more of the divalent alkylene or alkenyl groups, D represents a substituted or insubstituted divalent alkenyl, alkynyl, aralkyl alkoxycarbonyl or aryloxycarbonyl groups, X represents CH2, C=O, CH-OH, sulphur, oxygen, N-Y, where Y represents hydrogen, substituted or unsubstituted alkyl, aryl, aralkyl or acyl, Ar represents a divalent aromatic, single or fused ring system, with or without substituents, the ring may contain one or more hetero atoms selected from nitrogen, sulphur, or oxygen; R1and R2each represents hydrogen or together represent a bond either or both may be substituents or both together form a part of a ring. Methods for preparing the compound and pharmaceutical compositions containing a compound of formula (I).

Synthesis of novel succinamide derivatives having the 5,11-dihydro-6h- pyrido[2,3-b][1,4]benzodiazepin-6-one skeleton as potent and selective M2 muscarinic receptor antagonists. I

A series of 5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one derivatives containing the succinamide skeleton has been synthesized and evaluated for M1, M2 and M3 muscarinic receptor binding affinities (in vitro) and M2 and M3 muscarinic receptor antagonistic activities (in vivo). Some of them showed higher and more selective binding affinities for M2 muscarinic receptors than that of AF-DX 116. Among them, 11-[3-[N-[2-(N- benzyl-N-methylamino)ethyl]-N-ethylearbamoyl]propionyl]-5,11-dihydro-6H- pyrido[2,3-b][1,4]benzodiazepin-6-one (68) was found to be the most potent and selective M2 muscarinic receptor antagonist in vitro. This compound also strongly inhibited the oxotremorine-induced bradycardia after intravenous administration and showed 130-fold selectivity for M2 muscarinic receptors over M3 muscarinic receptors in vivo.

Alkylaminoalkylamine and ether compounds, processes and intermediates for their preparation, and medicaments containing them

Pharmacologically active compounds corresponding to the formula I STR1 in which n represents 2-5, m represents 2-6, R1 denotes hydrogen or lower alkyl, R2 represents an OR4 group in which R4 denotes lower alkyl

Process for the preparation of 2-(N-benzyl-N-methylamino)-ethyl methyl 2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate and its hydrochloride salt

A new, technologically easily feasible process for the preparation of 2-(N-benzyl-N-methylamino)ethyl methyl 2,6-dimethyl-4(m-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate, comprising a partrial hydrolysis of dimethyl 2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate in an inert organic solvent at a temperature between room temperature and the reflux temperature of the reaction mixture with an aqueous solution of alkali hydroxide and the reaction of the obtained 3-methoxycarbonyl-2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridine-5-carboxylic acid either with N-(2-hydroxyethyl)-N-benzyl-methylamine in the presence or absence of an organic solvent in the presence of N,N'-dicyclohexylcarbodiimide at a temperature of between 25° and 120° C. or with N-(2-haloethyl)-N-benzyl-methylamine in the presence of an inert organic solvent and of a proton acceptor at a temperature of between 25° and 140° C., to yield the title compound, which can be, if desired, converted to its hydrochloride salt. The hydrochloride salt is known under the generic name "nicardipine hydrochloride" and is used as a valuable therapeutic in the therapy of cerebral insufficiency.